Page History

•  Approve minutes from 06/27/2016
  
  

Decision from Copenhagen 2015, that the prescribing use case is not going to be supported. Thus the need for universal restrictions in the DL is not needed at this time.

Questions regarding the names of drug products that contain SOME substances if we disallow the use of universal restrictions:

-          Which concepts have this potential problem?

-          How to construct the FSN to make it unambiguous?

-          If we change the FSN, is it a technical correction or retire and replace? 

Policy on addition of assessment tool responses to the International edition.

IHTSDO currently accepts "names" of assessment instruments and staging scales; however, there is nothing in the editorial guide that specifically addresses the responses to assessment instrument questions. As many of these are extremely context dependent, being tied specifically to the particular instrument, what should be the policy of IHTSDO to requests to add assessment instrument responses to the International release.

Example: Requests to add responses to Tinetti balance assessment tool

The EAG has been asked to do a self evaluation after the first two years of operarion. We need to answer the following questions given that the role of the EAG is advisory.

1. Are the responsibilities of EAG members clear?
2. Are the topics that have been discussed relevant to the expectations of the members?
3. Is the operation of the committee satisfactory?
4. Does the group feel that it has made substantial progress over the first two years?
5. Should the EAG be continued for the next year?

Space Actions

We are meeting for a full day in New Zealand. Need substantive topics to move forward.